263 related articles for article (PubMed ID: 11550142)
1. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
2. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
[TBL] [Abstract][Full Text] [Related]
3. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
4. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
5. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
6. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
8. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
Jolly S; Kestin LL; Goldstein NS; Vicini FA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
[TBL] [Abstract][Full Text] [Related]
9. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA
Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087
[TBL] [Abstract][Full Text] [Related]
10. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A
J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014
[TBL] [Abstract][Full Text] [Related]
11. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ.
Ringberg A; Palmer B; Linell F; Rychterova V; Ljungberg O
Eur J Surg Oncol; 1991 Feb; 17(1):20-9. PubMed ID: 1847343
[TBL] [Abstract][Full Text] [Related]
12. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP
Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381
[TBL] [Abstract][Full Text] [Related]
13. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
14. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
15. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
[TBL] [Abstract][Full Text] [Related]
16. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis.
Ben-David MA; Kleer CG; Paramagul C; Griffith KA; Pierce LJ
Cancer; 2006 Jan; 106(1):28-34. PubMed ID: 16329136
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Reis-Filho JS; Cancela Paredes J; Milanezi F; Schmitt FC
Cancer; 2002 Apr; 94(7):2114-5; author reply 2115-6. PubMed ID: 11932917
[No Abstract] [Full Text] [Related]
18. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions.
Goldstein NS; Bassi D; Watts JC; Layfield LJ; Yaziji H; Gown AM
Am J Clin Pathol; 2001 Apr; 115(4):534-42. PubMed ID: 11293901
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
